US Patent

US9820961 — Fumarate ester dosage forms

Method of Use · Assigned to Banner Life Sciences LLC · Expires 2035-02-27 · 9y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions, methods for making them, and methods for treating subjects with fumarate esters, particularly in oral controlled release formulations.

USPTO Abstract

Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One embodiment described herein is a pharmaceutical composition comprising fumarate esters suspended in a lipid or lipophilic liquid with enhanced bioavailability.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1384 monomethyl-fumarate

Patent Metadata

Patent number
US9820961
Jurisdiction
US
Classification
Method of Use
Expires
2035-02-27
Drug substance claim
No
Drug product claim
Yes
Assignee
Banner Life Sciences LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.